BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs January 9, 2026
Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio January 7, 2026
DEM BioPharma Announces Poster Presentation Featuring DEM301 at the 2026 ASCO Gastrointestinal Cancers Symposium January 7, 2026
Newleos Therapeutics Announces Dosing of First Participant in SOAR Phase 2 Study of NTX-1472 for Social Anxiety Disorder January 6, 2026
